Remarke v. Endo Pharmaceuticals, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Remarke v. Endo Pharmaceuticals, Inc.

Sort by

Viewing results 1‒25 of 68

Covid-19 vaccines
Pfizer and Moderna forecast to almost double vaccine sales in 2022
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
October 18, 2021
US opioid epidemic
US states near $26bn opioid settlement with J&J, drug distributors
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
July 20, 2021
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
US opioid epidemic
J&J to pay $230m to settle New York state opioid case
...James added that the pharmaceutical company’s heavy marketing of opioids was partially motivated by quotas for sales staff....
June 26, 2021
Covid-19 vaccines
Africa will pay more for Russian Covid vaccine than ‘western’ jabs
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
February 25, 2021
FT AlphavilleCoronavirus
The ESG case for the Oxford/AstraZeneca vaccine
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
December 23, 2020
Coronavirus treatment
EU fast-tracks process for Pfizer and BioNTech’s Covid-19 vaccine
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
October 6, 2020
FT Live
Funding Biopharma Innovation
Strategies for investing in drug development and commercialization
Wednesday, 26 June345 Park Avenue South, New York, NY, USA
The Long ViewMichael Mackenzie
The coming earnings season could bring lofty stocks down to earth
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
July 11, 2020
US opioid epidemic
J&J verdict hits share prices across opioid industry
...Endo International, a pharmaceutical company, fell 9 per cent to $2.65; Teva, the Israeli drugmaker, lost 4.6 per cent to $7.08; and McKesson, another distributor, fell 3 per cent to $142.55 in late-morning...
August 27, 2019
US opioid epidemic
US opioid trial to go ahead after settlement talks fail
...Teva Pharmaceuticals, the only remaining manufacturer, fell 1.6 per cent to $7.38, after losing 3.5 per cent during the trading day....
October 18, 2019
News in-depthPharmaceuticals sector
Crispr puts first human in-body gene editing to test
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
January 7, 2020
FT Magazine
Opioids, bribery and Wall Street: the inside story of a disgraced drugmaker
...It has requested that one opioid — Opana ER, made by Endo Pharmaceuticals — be removed from the market because of patterns of abuse, but also approved Dsuvia, by AcelRx Pharmaceuticals, another fast-acting...
June 19, 2020
Jonathan Guthrie
The fallacy behind the rise of passive fund management
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
January 15, 2020
News in-depthCushman & Wakefield Inc
Cushman v the cleaner: the fight over non-competes
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
October 16, 2018
Special Report50 Ideas to Change the World
Liver success holds promise of 3D organ printing
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
March 5, 2018
News in-depthThe Big Read
Quantum computing: the power to think outside the box
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
September 3, 2018
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
News in-depthWeek in Review
Week in review, December 16
...The new system would probably be funded by the pharmaceutical groups that manufacture opioid medicines — such as Perdue Pharma, Endo and Depomed — which have been sharply criticised for fuelling the crisis...
December 15, 2017
News in-depthThe Big Read
Big Tech vs Big Pharma: the battle over US patent protection
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
October 16, 2017
News in-depthThe Big Read
US seeks a fix for its opioid addiction
...Among the most commonly named defendants are drugmakers such as Purdue Pharmaceuticals, which is privately owned, Johnson & Johnson, Allergan, Mallinckrodt, Endo and Teva; distributors such as McKesson,...
September 11, 2017
US & Canadian companies
Shire weighs spin-off for ADHD drugs division
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
August 3, 2017
US equities
Drugmaker Endo rises on leadership change
...Mr Campanelli previously served as chief executive of Par Pharmaceutical and joined Endo after the company bought Par in 2015....
September 23, 2016
US & Canadian companies
FTC sues Endo over ‘pay for delay’ deals
...The US competition watchdog is suing Endo Pharmaceuticals and several other drugmakers for agreeing “pay for delay” deals worth hundreds of millions of dollars to stall rivals’ introduction of cheaper generic...
March 31, 2016
Inside BusinessJonathan Ford
Valeant is the latest troubled roll-up to unravel
...The stunning collapse in the shares of Valeant, until recently a fast-growing Canadian pharmaceuticals company, has been garnering the headlines in recent days....
March 20, 2016
High yield bonds
Healthcare junk bonds sting investors
...Prices of bonds issued by a number of the companies that have been accused of overpricing — including Valeant Pharmaceuticals, Endo International and Mallinckrodt — have fallen sharply, pushing up yields...
October 1, 2015
The FT ViewPharmaceuticals sector
Shkreli and the true cost of high drug prices
...A number of listed pharmaceutical companies, including Valeant, Endo and Mallinckrodt, have made it their business to buy up branded off-patent remedies and pump up prices....
December 22, 2015
High yield bonds
Music shifts for credit investors in 2015
...Fears surrounding Valeant reverberated through to other junk-rated healthcare companies, including Endo International and Mallinckrodt....
December 30, 2015

Previous pagePage 1 of 3Next page